Company news

BeyondSpring, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cel...

October 19, 2021

BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical On...

September 19, 2021

BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress

September 15, 2021

BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

September 9, 2021

BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress

September 8, 2021

BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021

September 6, 2021

BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for...

August 30, 2021

BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China

August 25, 2021

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

August 3, 2021

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

July 13, 2021

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

June 16, 2021

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

June 15, 2021

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 9, 2021

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Indu...

June 7, 2021

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical...

June 6, 2021

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

June 3, 2021

BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

May 31, 2021

BeyondSpring Files 2020 Annual Report on Form 20-F

April 29, 2021

BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update

April 29, 2021

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2021

BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

March 30, 2021

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

December 16, 2020

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

December 9, 2020

BeyondSpring Announces Pricing of Ordinary Shares

November 18, 2020

BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates

November 16, 2020

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

November 16, 2020

BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

November 15, 2020

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

November 12, 2020

BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer

September 21, 2020

BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication

September 7, 2020

BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates

September 2, 2020

BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020

August 26, 2020

BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors

August 17, 2020

BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.

August 10, 2020

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

June 14, 2020

BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update

June 10, 2020

BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

June 2, 2020

BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

May 12, 2020

BeyondSpring Files 2019 Annual Report on Form 20-F

April 29, 2020

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

March 29, 2020

BeyondSpring’s Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy

March 22, 2020

BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19

March 10, 2020

BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors

January 22, 2020

BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China

January 5, 2020

BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update

December 17, 2019

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

November 5, 2019

BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia

October 22, 2019

BeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors

October 16, 2019

BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019

September 30, 2019

BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results

September 17, 2019

← Newer news releases

Calls

Decks

The 5 newest of 25 decks. Every deck is listed under its year.